Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

M. Gross-Goupil; T. G. Kwon; M. Eto; D. Ye; H. Miyake; S. I. Seo; S. S. Byun; J. L. Lee; V. Master; J. Jin; R. Debenedetto; R. Linke; M. Casey; B. Rosbrook; M. J. Lechuga Frean; O. Valota; E. Grande; D. I. Quinn

doi:10.1093/annonc/mdy283

Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

M. Gross-Goupil, T. G. Kwon, M. Eto, D. Ye, H. Miyake, S. I. Seo, S. S. Byun, J. L. Lee, V. Master, J. Jin, R. Debenedetto, R. Linke, M. Casey, B. Rosbrook, M. J. Lechuga Frean, O. Valota, E. Grande, D. I. Quinn

外科学

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

本文言語	英語
ページ（範囲）	viii303
ジャーナル	Annals of oncology : official journal of the European Society for Medical Oncology
巻	29
DOI	https://doi.org/10.1093/annonc/mdy283
出版ステータス	出版済み - 10月 1 2018

!!!All Science Journal Classification (ASJC) codes

血液学
腫瘍学

文献へのアクセス

10.1093/annonc/mdy283

他のファイルとリンク

引用スタイル

Gross-Goupil, M., Kwon, T. G., Eto, M., Ye, D., Miyake, H., Seo, S. I., Byun, S. S., Lee, J. L., Master, V., Jin, J., Debenedetto, R., Linke, R., Casey, M., Rosbrook, B., Lechuga Frean, M. J., Valota, O., Grande, E., & Quinn, D. I. (2018). Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii303. https://doi.org/10.1093/annonc/mdy283

Gross-Goupil, M, Kwon, TG, Eto, M, Ye, D, Miyake, H, Seo, SI, Byun, SS, Lee, JL, Master, V, Jin, J, Debenedetto, R, Linke, R, Casey, M, Rosbrook, B, Lechuga Frean, MJ, Valota, O, Grande, E & Quinn, DI 2018, 'Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii303. https://doi.org/10.1093/annonc/mdy283

@article{b6d83411ebc84b6e9e67b59206825066,

title = "Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results",

author = "M. Gross-Goupil and Kwon, {T. G.} and M. Eto and D. Ye and H. Miyake and Seo, {S. I.} and Byun, {S. S.} and Lee, {J. L.} and V. Master and J. Jin and R. Debenedetto and R. Linke and M. Casey and B. Rosbrook and {Lechuga Frean}, {M. J.} and O. Valota and E. Grande and Quinn, {D. I.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy283",

language = "English",

volume = "29",

pages = "viii303",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC)

T2 - ATLAS trial results

AU - Gross-Goupil, M.

AU - Kwon, T. G.

AU - Eto, M.

AU - Ye, D.

AU - Miyake, H.

AU - Seo, S. I.

AU - Byun, S. S.

AU - Lee, J. L.

AU - Master, V.

AU - Jin, J.

AU - Debenedetto, R.

AU - Linke, R.

AU - Casey, M.

AU - Rosbrook, B.

AU - Lechuga Frean, M. J.

AU - Valota, O.

AU - Grande, E.

AU - Quinn, D. I.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85068779865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068779865&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy283

DO - 10.1093/annonc/mdy283

M3 - Article

C2 - 32136705

VL - 29

SP - viii303

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -